Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir (BI 201335) in HIV/HCV Co-infected Patients (STARTVerso 4)
NCT01399619Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of faldaprevir in hepatitis C virus infection (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virological Response 12 Weeks Post Treatment at 60 weeks. Started Sep 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01399619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399619.